<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Impact Biomedical, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/impact-biomedical-inc</link>
    <description>Latest news and press releases for Impact Biomedical, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 03 Apr 2026 17:52:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/impact-biomedical-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d75cf751cc36e4753389b5.webp</url>
      <title>Impact Biomedical, Inc.</title>
      <link>https://6ix.com/company/impact-biomedical-inc</link>
    </image>
    <item>
      <title>Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans</title>
      <link>https://6ix.com/company/impact-biomedical-inc/news/impact-biomedical-inc-reports-going-concern-audit-opinion-in-2025-10-k-filing-while-continuing-strategic-merger-plans</link>
      <guid isPermaLink="true">https://6ix.com/company/impact-biomedical-inc/news/impact-biomedical-inc-reports-going-concern-audit-opinion-in-2025-10-k-filing-while-continuing-strategic-merger-plans</guid>
      <pubDate>Fri, 03 Apr 2026 17:52:00 GMT</pubDate>
      <description>HOUSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026, includes an audit opinion from Grassi &amp; Co., CPAs, P.C. that contains a &quot;going concern&quot; qualification. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph and do</description>
    </item>
    <item>
      <title>Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue</title>
      <link>https://6ix.com/company/impact-biomedical-inc/news/impact-biomedical-inc-ibo-announces-3ftm-us-patent-issue</link>
      <guid isPermaLink="true">https://6ix.com/company/impact-biomedical-inc/news/impact-biomedical-inc-ibo-announces-3ftm-us-patent-issue</guid>
      <pubDate>Mon, 18 Aug 2025 12:30:00 GMT</pubDate>
      <description>HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled “Composition and Method of Controlling Infectious Diseases with Functional Fragrances,” developed within IBO’s 3F™ technology platform. This patent relates to unique composition and method for controlling infectious diseases. It includes compositions and formulations of constituents found in plants and fragrances</description>
    </item>
    <item>
      <title>Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger</title>
      <link>https://6ix.com/company/impact-biomedical-inc/news/dr-ashleys-limited-and-impact-biomedical-inc-announce-strategic-merger</link>
      <guid isPermaLink="true">https://6ix.com/company/impact-biomedical-inc/news/dr-ashleys-limited-and-impact-biomedical-inc-announce-strategic-merger</guid>
      <pubDate>Mon, 23 Jun 2025 11:52:00 GMT</pubDate>
      <description>A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company (“Dr Ashleys”), and Impact BioMedical Inc. (“Impact BioMedical”) (NYSE American: IBO), a Texas based biopharmaceuticals developer listed on the New York Stock Exchange American (“Impact BioMedical”, together with Dr Ashleys, the “Parties”), are pleased to announce the execution of a merge</description>
    </item>
  </channel>
</rss>